Background and Objectives: Although randomized clinical trials (RCTs) are valuable tools to compare treatment effects, RCTs can���t usually extrapolate the results to the real-world populations because of different patients subsets by their specific inclusion and exclusion criteria. To categorize the risk of future cardiovascular events in drug-eluting stent (DES)-treated patients with coronary artery disease (CAD), we analyzed demographic, clinical and procedural data in all-comers who underwent percutaneous coronary intervention (PCI) Study Subjects and Methods: Patients who underwent PCI using DES from January 2004 were prospectively enrolled in the Catholic University of Korea-PCI (COACT) registry and were followed up for a median of 2 years. We analyzed the relationship of demographic, clinical and procedural data to the risk of clinical outcomes in the all-patient cohort, and a sub-analysis in subsets of angina and acute myocardial infarction (AMI) patients, respectively. The primary clinical outcome was a composite of death from any cause, nonfatal MI, stroke or any revasularization during long-term follow-up. Results: A total of 9127 patients who underwent implantation of DES were enrolled in the COACT registry. The patients were categorized into two groups consisting of those with angina (angina group, n=6183, 67.7% of total patients) and with AMI (AMI group, n=2944, 32.3% of total patients). The median follow-up duration was 757 days (interquartile range, 377 to 1272). Patients in the AMI group had more occurrence of the composite outcome of death, MI, stroke, or any revascularization during long-term follow up than those in the angina group (27.1 vs. 23.3%, p<0.001). However, in the landmark analysis of data from 1 year to 5 years, there was no significant difference in the primary clinical outcome between the two groups (p=0.44). In multivariable modeling, age (every 10 years, harzard ratio [HR], 1.13; 95% confidence interval [CI], 1.06-1.20; p<0.001), left ventricular ejection fraction (LV EF) (HR, 0.98; 95% CI, 0.97-0.99; p<0.001), and the presence of multivessel disease (HR, 1.42; 95% CI, 1.24-1.64; p<0.001) were associated with a siginicantly higher risk of the primary end point in the all-patients cohort, angina or AMI groups. Conclusions: We found that higher event rates in patients with AMI during long-term follow up after PCI are mainly attributed to higher mortality in first year. Some demographic, clinical and angiographic factors still significantly influence the long-term occurrence of major adverse cardiovascular events in the era of DES.